ALKS
What one share of Alkermes plc. holds
Pharmaceutical Preparations
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders.
Alkermes plc.’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $9.94 |
|---|---|
| Profit | $0.39 |
| Capex (buildings and equipment) | $0.18 |
| Free cash flow | $1.32 |
| Cash and investments | $3.05 |
| Debt | $8.97 |
| Book value | $10.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $4.92 | −$1.38 | $0.29 | −$0.71 | — | $7.93 |
| 2017 | $5.89 | −$1.03 | $0.33 | −$0.21 | — | $7.81 |
| 2018 | $7.05 | −$0.90 | $0.45 | $0.19 | — | $7.52 |
| 2019 | $7.46 | −$1.25 | $0.58 | −$0.12 | — | $6.88 |
| 2020 | $6.54 | −$0.70 | $0.27 | $0.26 | — | $6.70 |
| 2021 | $7.12 | −$0.29 | $0.17 | $0.45 | — | $6.87 |
| 2022 | $6.79 | −$0.97 | $0.23 | −$0.11 | — | $6.35 |
| 2023 | $9.80 | $2.10 | $0.28 | $2.08 | — | $7.20 |
| 2024 | $9.21 | $2.17 | $0.20 | $2.40 | — | $9.03 |
| 2025 | $8.75 | $1.43 | $0.24 | $2.85 | — | $10.99 |